Better Therapeutics Inc
Better Therapeutics, Inc., a prescription digital therapeutics company, develops a form of cognitive behavioral therapy to address the causes of cardiometabolic diseases. The company's lead product candidate is BT-001, an investigational PDT platform to treat type 2 diabetes. It also develops software-based prescription digital therapeutics platform candidates for treating diabetes, heart disease… Read more
Better Therapeutics Inc (BTTX) - Total Liabilities
Latest total liabilities as of September 2023: $20.66 Million USD
Based on the latest financial reports, Better Therapeutics Inc (BTTX) has total liabilities worth $20.66 Million USD as of September 2023.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Better Therapeutics Inc - Total Liabilities Trend (2019–2022)
This chart illustrates how Better Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Better Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Better Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Adamjee Insurance Company Ltd
KAR:AICL
|
Pakistan | PKRs152.92 Billion |
|
Arma Services Inc
PINK:ARMV
|
USA | $1.32 Million |
Liability Composition Analysis (2019–2022)
This chart breaks down Better Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.57 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -2.08 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.93 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Better Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Better Therapeutics Inc (2019–2022)
The table below shows the annual total liabilities of Better Therapeutics Inc from 2019 to 2022.
| Year | Total Liabilities | Change |
|---|---|---|
| 2022-12-31 | $23.84 Million | +67.45% |
| 2021-12-31 | $14.24 Million | +8.31% |
| 2020-12-31 | $13.14 Million | +139.61% |
| 2019-12-31 | $5.49 Million | -- |